WASHINGTON, Sept. 03, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60 Degrees Pharma” or the “Company”), a pharmaceutical company focused on developing new medicines for vector-borne diseases, announced today the webcast link and change of date for management’s live presentation at the H.C. Wainwright 27th Annual Global Investment Conference in New York City, to Tuesday, September 9, 3:30 PM Eastern Time.
Dr. Geoff Dow, 60 Degrees Pharma CEO, will present live and management will conduct one-on-one meetings during the conference.
Event: H.C. Wainwright 27th Annual Global Investment Conference
Date: September 9, 2025
Time: 3:30 PM ET
Location: Lotte New York Palace Hotel
Webcast: Register
About 60 Degrees Pharmaceuticals, Inc.
60 Degrees Pharmaceuticals, Inc., founded in 2010, specializes in developing and commercializing new medicines for the treatment and prevention of vector-borne disease. The Company achieved U.S. Food and Drug Administration approval of its lead product, ARAKODA® (tafenoquine), for malaria prevention in 2018. ARAKODA is commercially available in the U.S. and Australia. 60 Degrees Pharmaceuticals, Inc. also collaborates with prominent research and academic organizations in the U.S. and Australia. 60 Degrees Pharmaceuticals, Inc. is headquartered in Washington, D.C., with a subsidiary in Australia. Learn more at www.60degreespharma.com.
The statements contained herein may include prospects, statements of future expectations and other forward-looking statements that are based on management’s current views and assumptions and involve known and unknown risks and uncertainties. Actual results, performance or events may differ materially from those expressed or implied in such forward-looking statements.
Media Contact:
Sheila A. Burke
This email address is being protected from spambots. You need JavaScript enabled to view it.
(484) 667-6330
Investor Contact:
Patrick Gaynes
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$1.38 |
| Daily Change: | -0.04 -2.75 |
| Daily Volume: | 16,579 |
| Market Cap: | US$5.660M |
August 21, 2025 August 13, 2025 | |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
